IMP: BOD resolution dated February 09, 2023

The Board resolution dated February 09, 2023, the BOD of Imexpharm Corporation announced the following issues: Approved the business result in 2022: No Content 2022 % plan in 2022 2021 % Growth 1 Total revenue 1,668.2 115.1% 1,290.8 29.2% 2 Net sales 1,643.7 1,266.6 29.8% 3 Profit after tax 301.8 109.7% 238.9 26.3% Approved the business plan in 2023: No Content 2022 2021 % Growth 1 Net sales 1,620.0 1,643.7 -1.4% 2 Profit after tax 305.0 301.8 1.1% Approved the use of development investment fund for offsetting operating expenses in 2022 and 2023 with the total amount 17,266,310,029 dongs. Approved to authorize representatives for Imexpharm’s capital in Agimexpharm Pharmaceutical Joint-Stock Company: - Ms. Tran Thi Dao – Deputy Chairman of the BOD, General Director - Mr. Nguyen Quoc Dinh – Chairman of the BOD, Deputy General Director.